Compass Pathways Q3 Loss Narrows to $9.8M as Cash Builds to $444M
CMPS sits 89% above its 52-week low of $4.88 on elevated volume (5.8× avg).
Summary
Compass Pathways ended Q3 with $444.0 million in cash, enough to fund operations into 2028, while the reported $9.8 million net loss was flattered by a $40.8 million non-cash warrant remeasurement gain. Operating loss widened to $56.4 million as commercial-readiness spending ramped.
Key Events · Earnings and Guidance · CMPS
-
Q3 Net Loss Narrows on Non-Cash Warrant Gain
Net loss was $9.8 million, or $0.07 per basic share, versus $137.7 million a year earlier; the swing is driven by a $40.8 million non-cash fair-value gain on warrant liabilities, not operations.
-
Operating Loss Widens on Commercial Build-Out
Loss from operations widened to $56.4 million from $40.5 million as SG&A rose to $33.0 million from $13.2 million, partly offset by R&D falling to $23.5 million from $27.3 million after Phase 3 TRD completion.
-
Cash of $444.0 Million Funds Operations Into 2028
Cash and cash equivalents reached $444.0 million at September 30, 2026, up from $149.6 million at December 31, 2025, after $433.1 million of nine-month financing inflows including $203.2 million from 2025 ADS warrant exercises.
-
Hercules Covenant Kicks In October 2027
The amended Hercules facility provides up to $150.0 million with $50.0 million funded; a minimum cash covenant of 55% of outstanding debt begins October 1, 2027 unless market capitalization is at least $850.0 million.
Analysis · CMPS · Life Sciences
The headline number is an accounting illusion: the $9.8 million quarterly loss versus $137.7 million a year ago is mostly a $40.8 million non-cash gain on warrant remeasurement, not an operating improvement. Operations actually got more expensive — operating loss widened to $56.4 million from $40.5 million as selling, general and administrative spend nearly tripled to $33.0 million to build out commercial infrastructure ahead of a potential COMP360 launch. What matters is the balance sheet: $444.0 million of cash, up from $433.3 million at June 30, funds operations into 2028, and the company pulled in $433.1 million of financing over nine months, including full exercise of the 2025 ADS warrants for $203.2 million. Against that, the Hercules loan carries a minimum cash covenant starting October 1, 2027, and the Terran trade secret case survived summary judgment on September 25, 2026 with trial set for September 2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMPS was trading at $9.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.88 to $15.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.